LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC ("Alcon") to terminate the merger agreement between the parties.

We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unlikely to be met by the merger agreement's outside date of April 23, 2026 or the potential extended outside date of July 23, 2026. The Company will retain the $10.0 million deposit contemplated by the merger agreement.